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Abstract
Background: To compare the apparent diffusion coefficient (ADC) on diffusion-weighted imaging (DWI) with the
standardized uptake values (SUV) measured by18F-FDG-PET/CT in naïve hepatocellular carcinoma (HCC) nodules,
and to determine whether these markers are associated with tumours at high-risk of aggressiveness.
Methods: From 2007 to 2010, all patients with HCC on the waiting list for liver transplantation and who underwent
both FDG-PET/CT and 1.5-T DWI-MRI (b values: 0, 200, 400, and 800 s/mm2) were included in this institutional review
board-approved retrospective study. Tumour size, tumour ADC, tumour-to-liver ADC ratio (ADCT/L), maximal tumour
SUV and tumour-to-liver SUV ratio (SUVT/L) were measured and compared to serum alpha-fetoprotein (AFP) levels,
tumour size and differentiation grade on explanted specimens.
Results: A total of 37 HCC nodules in 28 patients were available for correlation between MRI and PET/CT, 7 of which
(in 7 patients) showed a SUVT/L > 1.15. We did not find any correlation between tumour ADC or ADCT/L and tumour
SUV or SUVT/L. To note, SUVT/L was positively correlated with AFP levels (R = 0.95, P≤ 0.0001), while ADCT/L was not (P
= 0.73). Twenty-four patients (with 32 nodules) underwent liver transplantation. In this subgroup, an increased SUVT/L
ratio was associated with larger tumours (average size, 32 ± 14 mm; range, 18–60 mm; P < 0.0001) and with poor
differentiation on pathology (grades 3 and 4; P = 0.04), while ADCT/L was neither associated with tumour size or
differentiation grade.
Conclusions: ADC and SUV measures in HCC nodules are not correlated. SUVT/L ratio correlates with AFP
levels, tumour size and poor differentiation, and should probably be integrated as a co-variable in a predictive
outcome model of patients on the waiting-list for liver transplantation.
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Background
While the prognosis of hepatocellular carcinoma (HCC)
without treatment is sombre, with 5-year life expectancy
below 7 %, optimal outcome is obtained in patients with
low tumour burden, eligible for liver transplantation
(LT) [1], especially within the Milan criteria [2]. Several
studies have reported that patients transplanted beyond
the Milan criteria can achieve long-term recurrence-free
survival: pathological features of HCC tumours appear
to play an important role as prognostic markers of
disease-free survival; increased alpha-fetoprotein (AFP)
levels, micro vascular invasion (MVI), differentiation
grade, and satellite nodules all appear to be associated
with impaired outcome following LT [3–9]. As a result,
the sole assessment of the number and size of HCC le-
sions in LT candidates is unable to precisely address the
risk of cancer recurrence after LT. As some pathological
prognostic markers such as MVI cannot be assessed on
biopsy specimens, growing interest has raised for the
evaluation of HCC using functional imaging as an ad-
junct to biology and conventional imaging for optimal
tumour grading.
Several studies have reported that pre-LT PET/CT
with [18F] 2- deoxy-2-fluoro-D-glucose (FDG) may play
a role in predicting tumour recurrence [10–15] in high-
grade HCC tumours, which have a reduced glucose-6-
phosphatase activity, resulting in progressive accumula-
tion of the tracer within tumour cells as compared to
adjacent liver. Hence, FDG standardized uptake value
(SUV) in HCC, as compared to adjacent normal liver
(tumour-to-liver ratio), reflects tumour aggressiveness,
including histological tumour grade and AFP levels,
which in turn correlate with outcome. For Lee et al., a
longer disease-free survival was observed after LT in pa-
tients with a tumour-to-liver ratio < 1.15, i.e., with less
than 15 % higher FDG uptake above normal liver back-
ground [16]. These data were later confirmed by
Kornberg et al., demonstrating the pejorative predictive
value of FDG-positive HCC [17].
Diffusion-weighted imaging (DWI) provides informa-
tion on the random Brownian motion of water mole-
cules within tissues, which reflects their cellularity.
Some authors have reported that high-grade HCC
tended to show decreased apparent diffusion coefficient
(ADC) values, as compared to well-differentiated tu-
mours [18], although this remains to-date debated [19].
Hence, both SUV and ADC could be considered as bio-
markers of HCC tumours at risk of recurrence following
LT, and could thereafter be tested as diagnostic and
prognostic tools for HCC management. To the best of
our knowledge, however, there have been no reports cor-
relating both markers in HCC. The aim of our study was
to measure and compare the ADC values on DWI with
SUVs measured by FDG-PET/CT in naïve HCC patients
on waiting-list for LT, and to determine whether these
markers can be associated with tumours at high risk of
aggressiveness using the pathology of explanted speci-
mens as the reference standard.
Methods
Patients
The local patient database was searched retrospectively
to identify all consecutive patients with HCC referred to
our institution for LT between 2007 and 2010, who
underwent both liver MRI and FDG-PET/CT prior to
LT as part of their work-up. During this period, 78 pa-
tients met the inclusion criteria. We excluded patients in
whom DWI sequences were not performed (n = 15), pa-
tients bearing liver lesions all < 10 mm on MRI (n = 13)
and patients who underwent percutaneous tumour abla-
tion or chemoembolization prior to either PET/CT or
liver MRI (n = 22). As a result, 28 patients were eligible,
including 23 men and 5 women, with a median age of
59 years (range, 46 to 69 years); 9 patients were Child-
Pugh A, 15 Child-Pugh B, and 4 Child-Pugh C; the
underlying liver disease in the study population is shown
in Table 1. Based on pre-LT imaging data, 67.8 % (19/
28) patients fulfilled the Milan criteria (2), and 82.1 %
(23/28) fulfilled the UCSF criteria [20]. All were included
in clinical trials, which were active at this time, and
signed informed written consent, in accordance with our
Institutional Review Board (Comité de Protection de
Personnes, Ile-de-France IX).
Fifteen patients underwent neo-adjuvant treatments
before LT, all of which were performed after both the
liver MRI and PET/CT: 13 patients underwent lipiodol-
doxorubicin based chemoembolization, either alone (n =
8) or combined with radiofrequency ablation (n = 3) and
surgery (n = 2); 2 patients underwent radiofrequency
Table 1 Patient population features
Patients (n) 28
Age (years) [Mean (±SD)] 59 ± 6
Sex ratio (Male/Female) 23/5





NASH + alcohol 2
Hepatitis C + alcohol 2
Hepatitis C + alcohol + hemochromatosis 1
Hemochromatosis + hepatitis C 1
NASH + hemochromatosis 1
NASH Non Alcoholic Steato-Hepatitis
Boussouar et al. Cancer Imaging  (2016) 16:4 Page 2 of 9
ablation prior to LT. MRI and PET/CT comparisons
were performed on treatment-naive HCC patients.
Magnetic resonance imaging
All MRI images were acquired on a 1.5-T MR imaging
system (Avanto®, Siemens Healthcare, Erlangen,
Germany) with Super Quantum gradients (maximum
gradient amplitude 40 mT/m, maximal gradient slope
200 mT/m), and an 18-channel total imaging matrix sys-
tem. The liver MRI protocol included transverse gradi-
ent recalled echo (GRE) in and out-of-phase T1
sequences (TR/TE/α: 119 ms/2.4–4.8 ms/70°; slice thick-
ness 5 mm), and breath-hold fat suppressed transverse
turbo spin echo (TSE) T2 sequences (TR/TE/α:
2400 ms/82 ms/150°; slice thickness 5 mm; echo train
length = 23). The DWI sequence was based on standard
single-shot diffusion-weighted spin echo planar imaging
with 4 b-values (0, 200, 400 and 800 s/mm2), and was
acquired prior to Gd-chelates injection. The DWI se-
quence was acquired with respiratory gating (Prospective
Acquisition Correction [PACE] system, average TR =
1500 ms, TE = 78 ms; slice thickness 5 mm; matrix
148x112; FOV 300x250 mm; Nex = 3; BW = 1342 Hz/
pixel; generalized autocalibrating partially parallel acqui-
sition factor 2). A dynamic breath-hold 3D volumetric
interpolated breath-hold examination (VIBE) T1WI
(TR/TE/α: 3.17 ms/1.33 ms/20°; slice thickness 3 mm;
mean acquisition time of 19 ± 3 s) was repeated before
and 4 times after injection of a total of 0.2 mL/kg gado-
teric acid (Dotarem®, Guerbet, Aulnay, France). Each 3D
VIBE was acquired at a 20 s interval.
All MR images were analyzed by 2 observers (SB,
ALu), blinded to PET/CT results. For each patient, the
number of lesions fulfilling the European Association for
the Study of Liver Disease and American Association for
the Study of Liver Disease (EASL-AASLD) [21] diagnos-
tic criteria on MRI was determined, thereafter defining
whether each patient fulfilled the Milan and UCSF cri-
teria [2, 20]. Analyses were performed on a commercially
available Siemens Workstation (Syngo MMWP, Siemens
Healthcare, Forchheim, Germany). In addition, for each
HCC nodule, the following parameters were measured:
size, location according to Couinaud liver segmentation,
T1 signal intensity (SI) relative to muscle, T2SI relative
to spleen. ADC maps were obtained using a mono-
exponential fit of the signal decrease on the 4 b values
on a voxel-by-voxel basis. A region of interest (ROI)
encompassing the entire lesion was placed on the b0
image, and then, propagated to the ADC map to provide
the mean tumour ADC (ADCT). The ADC of the nor-
mal liver parenchyma (ADCL) was also measured on the
right posterior segment of the liver, using a 20 mm ROI
positioned away from tumours, vessels, and bile ducts.
The tumour-to-liver ratio (ADCT/L) was computed for
each HCC lesion.
PET/CT imaging
The median delay between PET/CT and MRI was 3 days
(range, −181 to 245 days). All images were acquired
using an integrated PET/CT scanner (Gemini GXL16,
Philips, Da Best, The Netherlands). After fasting for at
least 6 h, patients were injected with an average
5.2 MBq/kg FDG, and images were acquired 1 h later. A
low-dose CT scan was obtained for attenuation correc-
tion and localization purposes (100 kV, 80 mAs),
followed by an emission scan from the top of the skull
to mid-thigh with 9–11 bed shifts of 2 min each. Images
were reconstructed using a line-of-response row action
maximum likelihood algorithm (LOR-RAMLA) with
matrix size of 144x144, and corrections for attenuation,
scatter and random coincidences. CT was obtained with-
out contrast enhancement.
PET, CT, and fused PET/CT images were analyzed on
a proprietary workstation (Syntegra, Philips, Milpitas,
CA). SUV was defined as tissue concentration of FDG
(kBq/mL) divided by the injected activity per weight
(MBq/kg). All images were analyzed by 2 observers (EI,
EE) blinded to MRI analysis. For each FDG-avid HCC
nodule, the following parameters were collected: location
of the tumour according to Couinaud liver segmenta-
tion, maximum SUV of the tumour (SUVT) and max-
imum SUV of the normal liver parenchyma (SUVL).
ROIs were drawn on 5 contiguous slices around each
focus of tumour uptake in order to capture the max-
imum SUV; in the normal liver parenchyma, ROIs were
drawn at mid height, making sure that VOI outlines
were restricted to areas of physiologic uptake and avoid-
ing neighbouring sites of disease. The tumour-to-liver
ratio (SUVT/L) was calculated for each lesion; when no
clear focus of uptake was identified, SUVT was consid-
ered equal to SUVL, and SUVT/L was set at 1.
Liver transplantation
Of the 28 patients, 24 were transplanted during the
study period, while 2 patients showed tumour progres-
sion and were dropped from the waiting list, 1 patient
was excluded of LT owing to aortic stenosis and 1 pa-
tient declined LT after registration. The median delay be-
tween MRI and LT was 117 days (range 1 to 446 days).
The median delay between PET/CT and LT was 104 days
(range, 23 to 394 days). In all cases, a bilateral subcostal
incision with an upper midline extension was performed.
LT was performed using preservation of the inferior vein
cava (IVC) and temporary porto-caval anastomosis ex-
cept when IVC resection was necessary. Reconstruction
was performed in the piggyback fashion with end-to-side
cava-caval anastomosis on the joined stump of the three
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main hepatic veins. Portal, arterial and biliary recon-
structions were performed using standard techniques.
Pathology examination – Correlation with imaging
findings
Explanted liver specimens were cross-sectioned and ana-
lyzed by a pathologist (JCa) blinded from imaging re-
sults. After formalin fixation, each liver slice was further
pared to less than 5 mm thickness. All liver nodules,
whether benign or consistent with HCC lesions, were
macroscopically located according to Couinaud classifi-
cation. The largest macroscopic diameter of each HCC le-
sion was recorded. For all HCC, at least a complete slice
of the tumour including both the centre and the periphery
was sampled for microscopic analysis. After hematoxylin-
eosin-saffran staining, each nodule was analyzed for the
presence of tumour cells. Microscopic evaluation of all tu-
mours included the assessment of the following: tumour
differentiation according to Edmondson-Steiner classifica-
tion, presence of a capsule, quantification of necrosis,
presence of MVI, and presence of satellite nodules. Pa-
tients with aggressive HCC were defined as presenting ei-
ther an undifferentiated HCC (Edmondson-Steiner grades
3 and 4), and/or a micro vascular invasion, or beyond
Milan criteria on the explanted specimen. Then, radiolo-
gists, nuclear medicine physicians and pathologist ensured
adequate correlation between imaging and pathological
data in a consensus meeting. Co-localization of tumours
on pathology and imaging was not only based on segmen-
tal classification but also on the identification of specific
landmarks such as hepatic veins, portal branches and cen-
tral or peripheral location. Only HCC nodules retrieved
simultaneously on pathology and on MRI were considered
for statistical analyses.
Statistics
The correlation between DWI-MRI and PET/CT variables
(ADCT, ADCL, ADCT/L, T1SI relative to muscle, T2SI
relative to spleen, SUVT, SUVL, SUVT/L) was analyzed
using Pearson’s correlation coefficients based on pair wise
complete data (37 nodules in 28 patients). In addition, be-
cause of possible erroneous ADC measures within the left
lobe, induced by cardiac motion, this correlation analysis
was repeated only for right lobe lesions. The association
between imaging features and pathological outcomes (32
nodules in 24 LT patients) were analyzed using the follow-
ing methods: 1) dichotomous outcomes (within/beyond
Milan criteria, absence/presence of MVI, differentiated/
undifferentiated HCC) vs. dichotomous FDG uptake
(PET/CT was considered positive if the ratio SUVT/L
was > 1.15 [16]) were analyzed based on categorical ana-
lyses using Fisher exact test; 2) dichotomous outcomes vs.
continuous imaging features (DWI-MRI and PET/CT var-
iables) were analyzed based on univariate logistic
regression; 3) continuous outcomes (differentiation status)
vs. all imaging features were analyzed based on univariate
linear regression. A P-value < 0.05 was considered statisti-




All 37 HCC nodules were > 10 mm on MRI with a mean
tumour size of 24 ± 10 mm (range, 11 to 60 mm), and
the mean ROI size for ADC measurements was 5 ±
19 voxels. The mean ADCT value of these lesions was
1.39 × 10−3 ± 0.35 × 10−3 mm2/s (range, 0.41 to 1.89 × 10
−3 mm2/s). The mean ADCL value was 1.36 × 10
−3 ±
0.37 × 10−3 mm2/s (range, 0.25 to 2.33 × 10−3 mm2/s).
The mean ADCT/L ratio was 1.13 ± 0.63 (range, 0.32 to
4.44).
PET/CT analysis
The mean SUVT of the 37 HCC lesions retrieved on
MRI was 2.9 ± 0.7 (range, 2.3 to 6.3). The mean SUVL
was 2.7 ± 0.3 (range, 2.3 to 3.6). The mean SUVT/L was
1.08 ± 0.28 (range, 1.00 to 2.63). Overall, using the
SUVT/L cut-off value of 1.15, PET/CT was considered
positive in 7 HCC in 7 patients: the mean SUVT was 3.8
± 1.2 in these nodules, accounting for a mean SUVT/L
ratio of 1.44 ± 0.53 (range, 1.19 to 2.63, Fig. 1).
Correlation between DWI-MRI and PET/CT
ADCT was not correlated with either SUVT, SUVL, or
SUVT/L ratio (Table 2, Figs. 2 and 3). ADCL did not cor-
relate either with SUVL, SUVT, or SUVT/L ratio. ADCT/L
ratio did not correlate with either SUVT/L ratio, SUVT,
or SUVL. Because ADC measurements may be less reli-
able in the left lobe of the liver due to cardiac motion,
we considered in a second analysis only lesions located
within the right lobe (n = 28): ADCT was not correlated
with either SUVT (R = 0.25, P = 0.3) or SUVT/L ratio (R
= 0.29, P = 0.21). ADCL did not correlate either with
SUVT (R = 0.24, P = 0.4) or SUVT/L ratio (R = 0.15, P =
0.57). ADCT/L ratio did not correlate with either SUVT
(R = −0.18, P = 0.46) or SUVT/L ratio (R = −0.12, P = 0.6).
Pathology
Gross examination revealed 32 HCC nodules in the 24
LT patients, accounting for a mean number of 1.3 le-
sions per patient (17 patients had 1 nodule, 6 had 2 nod-
ules, and 1 had 3 nodules). The mean size of these HCC
nodules was 21 ± 11 mm (range, 4 to 47 mm). Overall,
11 patients (46 %) met the Milan criteria based on the
pathological analysis of the explanted specimens. Eight
patients (33 %) showed at least one HCC lesion with
MVI. The Edmondson-Steiner histological grade for LT
was as follows: 2 lesions were grade 1, 7 lesions were
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grade 2, 17 lesions were grade 3, and 2 lesions were
grade 4; four lesions could not be graded because of sig-
nificant tumour necrosis.
Correlation between imaging variables and criteria of
aggressiveness
In the 28 patients on the waiting list, the median AFP
level for all Child Pugh stages was 4.7 ng/mL (range, 0.7
to 13,469.0 ng/mL). The median AFP levels did not dif-
fer between Child-Pugh stages A, B and C: 5.0 ng/mL
(range, 0.7 to 283.0 ng/mL), 4.6 ng/ml (range, 2.0 to
13,469.0 ng/mL), and 13.0 ng/mL (range, 2.2 to 33.0 ng/
mL), respectively (P = NS). SUVT/L ratio significantly
correlated with the AFP level (R = 0.95, P < 0.0001)
whereas no apparent correlation was detected between
AFP and ADCT or ADCT/L ratio (P = 0.08 and P = 0.73,
respectively). The mean AFP level was significantly
higher in patients with SUVT/L ratio > 1.15 than in PET/
CT-negative patients (1951.9 ± 5078.9 ng/mL vs. 26.3 ±
64.0 ng/mL, respectively; P < 0.0001). In the 24 trans-
planted patients, the mean HCC tumour size was also
significantly larger in patients with SUVT/L ratio > 1.15
than in PET/CT-negative patients (32 ± 14 mm vs. 23 ±
7 mm; P < 0.0001). Tumour size did not correlate with
ADCT values (P = 0.25). In addition, positive PET/CT
with SUVT/L ratio > 1.15 was associated with poor differ-
entiation on pathology (P = 0.04), but not with MVI or
Milan criteria (P =NS). None of the MRI variables - in-
cluding ADCT, ADCT/L, T1SI relative to muscle, and
T2SI relative to spleen - correlated with pathological
outcomes, including differentiation grade, MVI and
Milan criteria.
Discussion
DWI-MRI and FDG-PET/CT provide distinct functional
and morphological information. To date, MRI or en-
hanced CT are essential for HCC lesion detection and
characterization according to practice recommendations,
while FDG-PET/CT is not. This study sought to evaluate
the correlation between metabolic and DWI parameters,
and to compare these parameters with established bio-
markers of tumour aggressiveness and prognostic assess-
ment. Increased FDG uptake within HCC nodules was
associated with larger and less differentiated tumours,
whereas ADC values observed in this study population
appear not to correlate with AFP, differentiation on
pathology and Milan criteria.
Duvoux et al. have suggested that AFP levels could
predict tumour recurrence and correlated with vascular
invasion and differentiation with a significant increase in
5-year risk of recurrence (50.6 %). Among patients






Fig. 1 Poorly differentiated HCC in a patient with alcoholic cirrhosis, showing restricted ADC on DWI-MRI and increased uptake on the FDG-PET/CT.
Transverse dynamic contrast-enhanced initial post contrast MR image shows a 30 mm large nodular enhancing lesion in the right liver on 3D GE arterial
phase imaging (a, arrow) with wash-out on portal-venous phase (b, arrow). The lesion is mildly hyper intense on transverse DW image (b = 800 s/mm2;
c, arrow) and has a low ADC (1.06 × 10−3 mm2/s) on the ADC map (d, arrow). FDG-PET/CT shows an increased tumour uptake with a SUVT = 4.1 and
SUVT/L = 1.24 (e, arrow). The explanted liver showed an Edmondson-Steiner grade 4 HCC (f, arrow)
Table 2 Correlations between ADC and SUV values. Pearson’s
correlation coefficients (R) and P-values (P) do not show any
correlation between pair wise parameters
SUVL SUVT SUVT/L
R P R P R P
ADCL 0. 17 0.36 0.14 0.44 0.04 0.81
ADCT 0.03 0.87 −0.01 0.98 −0.09 0.58
ADCT/L −0.09 0.61 −0.12 0.5 −0.1 0.58






Fig. 2 Moderately differentiated (grade 2) HCC in a patient with hepatitis B-induced cirrhosis, showing restricted ADC on DWI-MRI and no significant
uptake on FDG-PET/CT. MR imaging showed a left lobe HCC with high T1 (a, arrow), high T2 (b, arrow) signal intensity, with arterial enhancement
(c, arrow) followed by washout (d, arrow). The HCC showed high signal intensity on DWI image (b = 800 s/mm2; e, arrow) consistent with low ADC







Fig. 3 Poorly differentiated HCC in a patient with left lobe HCC, showing no restricted ADC on DWI-MRI and increased uptake on FDG-PET/CT.
Dynamic 3D gradient echo T1 WI shows a non enhancing nodule on arterial phase (a, arrow), remaining hypo intense on portal phase (b, arrow)
but associated to a thin peripheral enhanced rim. The nodule shows high signal intensity on DWI image with b = 0 s/mm2 (c, arrow) decreasing
on DWI b = 800 s/mm2 images (d, arrow), although its signal intensity remained higher than the liver. The tumour ADC was 1.38 × 10−3 mm2/s
(e, arrow), similar to that of the adjacent liver. The lesion proved positive on FDG-PET/CT (f)
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AFP levels > 1000 ng/mL showed at high risk of recur-
rence [9]. Our study confirms that PET/CT findings cor-
relate with AFP levels. PET/CT was considered positive
if the SUVT/L ratio was > 1.15, which occurred in 7 pa-
tients on the waiting list (25 %), of whom 2 demon-
strated tumour progression and did not undergo LT.
Higher-grade and less-differentiated tumours (according
to Edmondson-Steiner classification) were associated
with higher levels of FDG accumulation. Decreased
levels of glucose-6-phosphatase observed in poorly dif-
ferentiated HCC lead to increased FDG accumulation
[10, 22]. Our results confirm the performance of FDG-
PET/CT in predicting tumour aggressiveness using the
explanted specimen as the reference standard. In
addition, PET/CT performed once as a screening tool
even as far as a median 104 days prior to LT still corre-
lates with pathological features of HCC.
The ADC value, measured by DWI, usually reflects
tumour cellularity as well as interstitial tissue assessment.
The mean ADCT values observed in this study are com-
parable to those reported in the literature [18, 23]. Simi-
larly, ADCT/L ratios observed in this study are not high,
reflecting the low contrast between the tumour lesions
and adjacent liver on ADC maps [24–26]. This could be
partly explained by the restricted diffusion observed in
liver fibrosis [27]. There have been conflicting reports re-
garding the link between ADC values and HCC differenti-
ation: for some, although differences are not significant in
terms of parametric ADC values, a higher signal intensity
of HCC lesions in DWI is usually associated with higher
pathological grades [18, 19]. However, the reasons ac-
counting for an increase in mean ADC values vary:
tumour necrosis is responsible for reduced cellularity and
increased ADC [28]; on the opposite, increased necrosis is
also observed in highly aggressive HCC lesions with active
portions of the tumour mostly located at the periphery of
the lesions [29]. Last, tumour vascularization impacts
ADC measurements, especially when low b-values are in-
cluded, such as in this study where 4 b-values were used,
including b = 0 s/mm2. As multiple b-value acquisitions
were not studied, the specific influence of the perfusion
component of diffusion in predicting tumour aggressive-
ness could not be tested here. In addition, the ADC mea-
surements encompassed the entire HCC lesions, reflecting
all components of the tumour observed on a single slice
rather than on the entire tumour volume, which could
also have limited the performances of ADC measure-
ments. FDG uptake on the other hand correlates with the
metabolic activity of viable tumour cells. Although necro-
sis decreases the overall tumour uptake, the SUV is mea-
sured from the area of highest uptake within the lesion
set; the SUV only considers the most aggressive tumour
components. Comparing mean ADC to maximum SUV
does not reflect a true comparison of the most active
component of each lesion. Moreover, a majority of HCC
lesions observed in our study showed similar SUV values
as compared to the adjacent liver, thus reducing the
dispersion of SUV values as compared to ADC measure-
ments. The use of novel tracers such as 18F-fluoromethyl-
choline (FCH) could allow a better distribution of uptake
values in HCC lesions even in well-differentiated HCC
lesions.
In contrast with previous publications, this study fo-
cused on patients on waiting list for LT, using pathology
of explanted specimens as the reference standard in a
large majority of them. Moreover, there have been con-
flicting reports on the correlation between DWI and
PET/CT in HCC, as tissue cellularity and glucose me-
tabolism may represent 2 different facets of tumour
biology [30]: some studies have suggested a positive cor-
relation between tumour SUVs and ADC values [31–37].
Other authors have reported an inverse relationship be-
tween these parameters, especially when discriminating
malignant from benign lesion, or when predicting the
aggressiveness of some tumours [31, 33–39]. Hypercellu-
lar areas could increase impedance to water diffusion,
resulting in low ADC values and high FDG uptake, while
lower cellularity areas could show increased ADC with
decreased FDG uptake. These relationships were re-
ported mainly in extra-digestive tumours possibly be-
cause the influence of motion on ADC measurements is
more limited in this setting. This further suggests the
need to test DWI-MRI together with multitracer PET
(FDG and/or FCH) in dedicated PET/MR platforms
allowing simultaneous acquisitions and limited influence
of motion on parametric imaging analysis [40].
Several limitations of the presented study have to be
mentioned. First, the patient population was small in
this monocentric retrospective study. There is currently
no national recommendation for systematic FDG-PET/
CT in routine before LT. Second, only patients on LT
waiting list were considered eligible, which prevented in-
clusion of more aggressive and larger tumours. The
study design further excluded patients who were treated
with chemoembolization, radiofrequency, and chemo-
therapy before DWI-MRI because these treatments alter
ADC measures [41, 42]. Interestingly, 15 patients were
treated between MRI and LT, which could possibly have
impacted the correlation between imaging and pathology
[41, 42]. However, this did not affect the SUV and ADC
correlation as all correlations were made on imaging ex-
aminations performed prior to any treatment. There was
no image fusion between PET/CT and DWI-MRI; how-
ever, to our knowledge and to-date, no software enables
the correct simultaneous fusion between b-maps, ADC
maps and PET/CT images.
PET/CT was obtained without contrast. However this
did not impact the co-registration of MRI images: all
Boussouar et al. Cancer Imaging  (2016) 16:4 Page 7 of 9
MRI lesions were detected on both FDG-PET/CT and
on pathology. Additionally, it is important to note that
only patients meeting the EASL-AASLD criteria were in-
cluded, limiting the analysis to lesions larger than
10 mm with early enhancement on arterial phase. How-
ever, the aim of this study was not to assess the perform-
ance of each modality for the detection of HCC in
patients on waiting list for LT, for which MRI plays a
key role, but to study the possible predictive nature of
FDG-PET/CT or DWI sequences on tumour aggressive-
ness. The median delay between FDG-PET/CT and
MRI-DWI was 3 days with a maximum of 245 days.
FDG-PET/CT and DWI-MRI datasets were evaluated
separately without knowledge of the findings of the
other imaging modality and without knowledge of histo-
pathology findings.
Conclusions
Although mean ADC and FDG-PET/CT maximum SUV
of HCC in patients on waiting list for LT are not corre-
lated, both tumour size, poor differentiation and AFP
levels correlate with SUVT/L, suggesting that FDG-PET/
CT can predict tumour aggressiveness and should prob-
ably be integrated as a covariable in a predictive outcome
model of patients with HCC candidate to LT, while MRI
must be used for lesion detection and characterization.
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